93 related articles for article (PubMed ID: 30231226)
1. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
DiNardo CD
N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30231226
[No Abstract] [Full Text] [Related]
2. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
Yun S; Vincelette ND
N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30260155
[No Abstract] [Full Text] [Related]
3. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
Sahin I
N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30260154
[No Abstract] [Full Text] [Related]
4. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
6. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
[TBL] [Abstract][Full Text] [Related]
7. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Takahashi K
Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457
[No Abstract] [Full Text] [Related]
8. Ivosidenib Deemed Safe, Effective in AML.
Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
[TBL] [Abstract][Full Text] [Related]
9. Ivosidenib and Azacitidine in IDH1-Mutated AML.
Goodman AM; Mohyuddin GR; Prasad V
N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
[No Abstract] [Full Text] [Related]
10. Ivosidenib and Azacitidine in IDH1-Mutated AML.
Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF
N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448
[No Abstract] [Full Text] [Related]
11. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Montesinos P; de Botton S; Döhner H
N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450
[No Abstract] [Full Text] [Related]
12. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
Rabehi T; Quesada S
Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
[No Abstract] [Full Text] [Related]
13. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.
Yue Z; Pan C; Wang S; N Tse A; Sheng Y
Eur J Clin Pharmacol; 2024 Jan; 80(1):105-113. PubMed ID: 37917187
[TBL] [Abstract][Full Text] [Related]
14. [Detection of the IDH1 gene mutation in acute myeloid leukemia by PCR-high resolution melting analysis].
Lin J; Qian J; Yao DM
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):484-6. PubMed ID: 22213873
[No Abstract] [Full Text] [Related]
15. Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF; Xu WR
Clin Biochem; 2011 Jul; 44(10-11):779-83. PubMed ID: 21539821
[TBL] [Abstract][Full Text] [Related]
16. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
[TBL] [Abstract][Full Text] [Related]
18. Ivosidenib effective in IDH1-mutant AML.
Sidaway P
Nat Rev Clin Oncol; 2018 Aug; 15(8):472. PubMed ID: 29925981
[No Abstract] [Full Text] [Related]
19. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mutant IDH1 in acute myeloid leukaemia.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
[No Abstract] [Full Text] [Related]
[Next] [New Search]
